Results 11 to 20 of about 1,250,673 (409)

The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant [PDF]

, 2013
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials.
Akira, S, Aoshi, T, Coban, C, Dessailly, BH, Ishii, KJ, Ito, J, Jounai, N, Kobiyama, K, Kuroda, E, Mizuguchi, K, Ohata, K, Tang, CK   +11 more
core   +8 more sources

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

New England Journal of Medicine, 2021
BACKGROUND Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality.
A. Tutt, J. Garber, B. Kaufman, G. Viale, D. Fumagalli, P. Rastogi, R. Gelber, E. de Azambuja, A. Fielding, J. Balmaña, S. Domchek, K. Gelmon, S. Hollingsworth, L. Korde, B. Linderholm, H. Bandos, E. Senkus, J. Suga, Z. Shao, Andrew W. Pippas, Z. Nowecki, T. Huzarski, P. Ganz, P. C. Lucas, N. Baker, S. Loibl, R. McConnell, M. Piccart, R. Schmutzler, G. Steger, J. Costantino, A. Arahmani, N. Wolmark, E. McFadden, V. Karantza, S. Lakhani, G. Yothers, C. Campbell, C. Geyer   +38 more
semanticscholar   +1 more source

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

New England Journal of Medicine, 2021
BACKGROUND No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.
R. Kelly, J. Ajani, J. Kużdżał, T. Zander, E. Van Cutsem, G. Piessen, G. Mendez, J. Feliciano, S. Motoyama, A. Lièvre, H. Uronis, E. Elimova, C. Grootscholten, K. Geboes, S. Zafar, S. Snow, A. Ko, K. Feeney, M. Schenker, Piotr Kocoń, Jenny Zhang, Lili Zhu, M. Lei, Prianka Singh, K. Kondo, J. Cleary, M. Moehler   +26 more
semanticscholar   +1 more source

Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

New England Journal of Medicine, 2023
BACKGROUND Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage
S. Patel, M. Othus, Yuanbin Chen, G. Wright, K. Yost, John R Hyngstrom, S. Hu-Lieskovan, C. Lao, L. Fecher, T. Truong, Jennifer Eisenstein, S. Chandra, J. A. Sosman, K. Kendra, Richard C Wu, C. Devoe, G. Deutsch, A. Hegde, M. Khalil, Ankit Mangla, A. Reese, M. Ross, A. Poklepovic, G. Phan, A. Onitilo, Demet Yaşar, Benjamin Powers, G. Doolittle, G. In, Niels Kokot, G. Gibney, M. Atkins, M. Shaheen, J. Warneke, A. Ikeguchi, J. E. Najera, B. Chmielowski, J. Crompton, J. Floyd, E. Hsueh, K. Margolin, W. Chow, K. Grossmann, E. Dietrich, V. Prieto, M. Lowe, E. Buchbinder, John M. Kirkwood, L. Korde, J. Moon, E. Sharon, V. Sondak, A. Ribas   +52 more
semanticscholar   +1 more source

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.

New England Journal of Medicine, 2022
BACKGROUND The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence.
J. Tie, J. Cohen, Kamel Lahouel, S. Lo, Yuxuan Wang, S. Kosmider, R. Wong, J. Shapiro, Margaret Lee, S. Harris, A. Khattak, M. burge, M. Harris, J. Lynam, L. Nott, F. Day, T. Hayes, S. McLachlan, Belinda Lee, Janine Ptak, Natalie Silliman, L. Dobbyn, M. Popoli, R. Hruban, A. Lennon, N. Papadopoulos, K. Kinzler, B. Vogelstein, C. Tomasetti, P. Gibbs   +29 more
semanticscholar   +1 more source

Adjuvant Migraine Medications in the Treatment of Sudden Sensorineural Hearing Loss. [PDF]

, 2021
Objectives/hypothesisTo examine the hearing outcomes of patients with sudden sensorineural hearing loss (SSNHL) treated with oral and intratympanic (IT) steroid only or a combination of steroid and migraine treatment.
Abouzari, Mehdi, Chua, Janice T, Djalilian, Hamid R, Goshtasbi, Khodayar, Lin, Harrison W, Saber, Tina, Sarna, Brooke, Tan, Donald   +7 more
core   +1 more source

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.

New England Journal of Medicine, 2021
BACKGROUND— The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear.
D. Bajorin
semanticscholar   +1 more source

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

New England Journal of Medicine, 2021
BACKGROUND Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence. METHODS In a double-blind, phase 3 trial, we randomly assigned, in
T. Choueiri, P. Tomczak, S. Park, B. Venugopal, T. Ferguson, Yen‐Hwa Chang, J. Hajek, S. Symeonides, Jae Lyun Lee, N. Sarwar, A. Thiery-Vuillemin, M. Gross-Goupil, M. Mahave, N. Haas, P. Sawrycki, H. Gurney, C. Chevreau, B. Melichar, Evgeniy Kopyltsov, A. Alva, J. Burke, G. Doshi, D. Topart, S. Oudard, H. Hammers, H. Kitamura, J. Bedke, R. Perini, Pingye Zhang, K. Imai, Jaqueline Willemann-Rogerio, D. Quinn, T. Powles   +32 more
semanticscholar   +1 more source

S-540956, a CpG Oligonucleotide Annealed to a Complementary Strand With an Amphiphilic Chain Unit, Acts as a Potent Cancer Vaccine Adjuvant by Targeting Draining Lymph Nodes

Frontiers in Immunology, 2021
Robust induction of cancer-antigen-specific CD8+ T cells is essential for the success of cancer peptide vaccines, which are composed of a peptide derived from a cancer-specific antigen and an immune-potentiating adjuvant, such as a Toll-like receptor ...
Takayuki Nakagawa, Tetsuya Tanino, Motoyasu Onishi, Soichi Tofukuji, Takayuki Kanazawa, Yukichi Ishioka, Takeshi Itoh, Akira Kugimiya, Kazufumi Katayama, Takuya Yamamoto, Morio Nagira, Ken J. Ishii, Ken J. Ishii, Ken J. Ishii   +13 more
doaj   +1 more source

Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels [PDF]

, 2015
BACKGROUND: Adjuvant zoledronic acid (za) appears to improve disease-free survival (dfs) in women with early-stage breast cancer and low levels of estrogen (lle) because of induced or natural menopause.
Lamond, Nathan W D, Rayson, Daniel, Skedgel, Christopher, Younis, Tallal   +3 more
core   +1 more source